ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus Production

 ABVC BioPharma, Inc. (NASDAQ: ABVC) ("ABVC" or the "Company") today announced that it has received a US$70,000 licensing payment from its partner, ForSeeCon Eye Corporation ("ForSeeCon"), under their global licensing agreement for Vitargus®, the world's first biodegradable vitreous substitute. With this latest payment, ForSeeCon has now paid a cumulative total of US$566,000 to ABVC under the agreement, which carries a potential value of up to US$30 million in equity consideration[1], US$3.5 million in cash licensing payments, plus up to US$60 million in future royalties - representing a total potential value of up to US$93.5 million.

Strong Financial Impact

Since the start of fiscal 2025, ABVC has received a total of US$1,345,950 in licensing revenues across all current partnerships. These licensing revenues come with minimal incremental costs, as development expenses were largely incurred in prior years. Thus far, this structure has enabled ABVC to capture high-margin revenues, directly enhancing its financial position while supporting strategic reinvestments; management expects that to continue.

Strategic Use of Proceeds

ABVC will allocate this new licensing income to its Good Manufacturing Practice (GMP) pharmaceutical facility in Hsinchu, Taiwan, with the specific goal of preparing for the GMP-compliant production of Vitargus®. This facility represents a critical milestone in moving Vitargus® from development into scalable, regulatory-compliant manufacturing, which is necessary for future commercialization.

About ForSeeCon Eye Corporation

ForSeeCon Eye Corporation is a strategic partner of ABVC, focused on ophthalmic innovation and commercialization. Under the licensing agreement, ForSeeCon obtained rights to develop and commercialize Vitargus®, a novel vitreous substitute designed to improve retinal surgery outcomes by eliminating the need for face-down positioning during recovery. Independent market research estimates the global vitreous substitute market at US$2.5 billion in 2024, projected to grow to US$4.1 billion by 2033.[2]

Management Commentary

Dr. Uttam Patil, ABVC's Chief Executive Officer, stated:
"We are pleased to receive this additional US$70,000 licensing payment from ForSeeCon, bringing their cumulative payments under the agreement to more than half a million dollars . In 2025 alone, ABVC has already secured US$1.35 million in licensing revenues across multiple partnerships. These high-margin revenues enable us to reinvest directly into our GMP pharmaceutical facility in Hsinchu, where we are laying the groundwork for Vitargus® GMP-compliant production. This is a critical step toward moving Vitargus® to commercialization and helping to deliver long-term value for our shareholders."

Forward-Looking Outlook

ABVC's licensing framework with multiple licensing partners, including AiBtl, ForSeeCon, and OncoX, and the potential to receive more than US$12 million in future receivables, we believe that ABVC remains well positioned to capture both near-term liquidity and long-term growth opportunities in CNS, oncology, and ophthalmology.

ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships.

Forward-Looking Statements

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

Contact:
Uttam Patil
Email: uttam@ambrivis.com